Oncohematological
Laboratorios Farma

Bioyetin active ingredient:

Recombinant Human Erythropoietin or Erythropoietin alpha or Erythropoietin beta

Bioyetin indications:

• Symptomatic anemia associated with chronic kidney disease in adults and children aged 1–18 years on hemodialysis and in adults on peritoneal dialysis.
• Severe anemia of renal origin accompanied by clinical symptoms in adults with kidney disease not yet on dialysis.
• Anemia with reduced transfusion requirements in adults receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, in whom assessment of general condition (e.g., cardiovascular status, anemia prior to initiation of chemotherapy) indicates a risk for transfusion.
• To increase autologous blood yield in adults enrolled in a predonation program. Only administer to patients with moderate anemia (Hb 10-13 g/dl, [6.2-8.1 mmol/l], without iron deficiency) if blood-sparing procedures are unavailable or insufficient when planned major elective surgery requires a large blood volume (4 or more units in women or 5 or more in men).
• To reduce the need for allogeneic blood transfusions in adults without iron deficiency before major elective orthopedic surgery, who are at higher risk of transfusion complications. Restrict to patients with moderate anemia (e.g., Hb 10-13 g/dl) for whom an autologous blood predonation program is not available and in whom moderate blood loss (900 to 1,800 ml) is expected.
• Symptomatic anemia (Hb ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).

Bioyetin presentation:

• 4.000 UI/ml ampoules x 6

• 50.000 UI/10 ml ampoules x 1

Prospecto

Filatil active ingredient:

Filatil indications:

• To reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with conventional cytotoxic chemotherapy for malignant diseases (except chronic myeloid leukemia and myelodysplastic syndromes).
• To reduce the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation who are at increased risk of prolonged severe neutropenia. Peripheral blood progenitor cell (PBPC) mobilization in children and adults with severe congenital, cyclic, or severe idiopathic neutropenia, to increase neutrophil counts and reduce the incidence and duration of infections. To treat persistent neutropenia with advanced HIV infection to reduce the risk of bacterial infections when other options for treating neutropenia are inadequate. Treatment of persistent neutropenia (ANC equal to or less than 1.0 x 10/L) in patients with advanced HIV infection to reduce the risk of developing bacterial infections when other options for treating neutropenia are inadequate.

Filatil presentations:

• Injectable solution (subcutaneous) 300 mcg/ml (1 vial)
• Prefilled syringe 300 mcg/ml per syringe

Prospecto